October 27th, 2010
Meta-Analysis Examines Risk Associated with CYP2C19 Genotypes
Larry Husten, PHD
There has been widespread debate and disagreement over the clinical significance of people with reduced function CYP2C19 genotypes who take clopidogrel. In an effort to shed light on the topic, Jessica Mega and colleagues analyzed data from 9685 patients enrolled in nine clinical trials. Some 26% of patients had 1 reduced-function allele, and 2% had 2 reduced-function alleles.
In a paper in JAMA, the investigators report a “directionally consistent risk for all of the components of the composite end point associated with carriage of 1 or 2 reduced-function CYP2C19 alleles.” The hazard ratios for cardiovascular death, nonfatal MI, and stroke among those with 1 or 2 alleles were 1.84, 1.45, and 1.73, respectively. The researchers conclude that, given the widespread use of clopidogrel, “determination of the optimal antiplatelet treatment doses or regimens for individual patients is needed to tailor therapy appropriately.”
In an accompanying editorial, Valentin Fuster and Joseph Sweeny write that the presence of at least one loss-of-function allele in nearly 30% of the population “confirms that the prevalence of reduced-function alleles might not be as insignificant as previously thought.” On the other hand, “it is uncertain whether these new findings in high-risk patients actually support the use of … genetic testing,” since platelet reactivity depends on multiple genetic and nongenetic factors. They conclude that “in patients treated with clopidogrel, the best genome-guided strategy remains to be determined.”
Categories: General, Interventional Cardiology
Tags: clopidogrel, clopidogrel genotyping, CYP2C19, meta-analysis
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
Comments are closed.
-
NEJM Journal Watch — Recent Cardiology Articles
- Recovery from Metabolic Syndrome Reduces Cardiovascular Risk
- Percutaneous Treatment of Tricuspid Regurgitation?
- Assessing the Progression of Stage B Aortic Regurgitation: Are the Guidelines Right?
- Does Testosterone Therapy Confer Risk for Venous Thromboembolism?
- Does ARNI Therapy for Heart Failure with Reduced Ejection Fraction Improve Health Status?
-
Sign up for NEJM Journal Watch Cardiology Alerts
Receive a free weekly email with the latest summaries on Cardiology.
-
Physician's First WatchToday's breaking medical news
-
Tag Cloud
- ACS AF AHA American Heart Association anticoagulation aortic valve replacement apixaban aspirin atrial fibrillation CABG cardiovascular risk cholesterol clopidogrel dabigatran diabetes diet drug-eluting stents epidemiology ESC exercise FDA Fellowship training guidelines HDL heart failure hypertension ICDs MI myocardial infarction obesity PCI Primary PCI risk factors rivaroxaban statins STEMI stents stroke stroke prevention TAVI TAVR type 2 diabetes venous thromboembolism warfarin women